Introduction
============

Schizophrenia is a psychiatric disorder that affects ∼1% of population. The main clinical features are positive symptoms (delusions, hallucinations and thought disorder), negative symptoms (social withdrawal and flattening of emotional responses) and cognitive impairment (attention and memory deficits).^[@bib1],\ [@bib2]^ There is a strong genetic association^[@bib3]^ and a common association with prenatal infection.^[@bib4]^ Prenatal infection (bacterial and viral) and the resulting inflammation may affect development of cortical neurons as demonstrated in rat models.^[@bib5],\ [@bib6],\ [@bib7]^ Increasing evidence suggests distinct immunological alterations in schizophrenia. These include elevations in acute phase proteins (haptoglobin, fibrinogen, complement, acid glycoprotein and hemopexin),^[@bib8]^ and alterations in plasma pro-inflammatory cytokines such as IL-1RA, sIL2R and IL-6 have also been reported.^[@bib9]^

Bipolar disorder represents a category of mood disorders defined by episodes of hypomania/mania (feelings of elation with elevated energy/activity levels and reduced sleep) and episodes of depression (low mood, anhedonia, low energy levels, loss of motivation, change of sleep and appetite).^[@bib10]^ It affects ∼2% of the general population.^[@bib11]^ For many sufferers, genetic factors have an important role in the aetiology.^[@bib10]^ In addition, several studies report elevated levels of pro-inflammatory cytokines in bipolar patients compared with healthy controls (HC). Specifically, elevated plasma levels of tumour necrosis factor-α (TNFα),^[@bib12],\ [@bib13],\ [@bib14]^ interleukin-2 (IL-2) and interleukin-4 (IL-4)^[@bib14],\ [@bib15]^ have been reported in manic bipolar patients whereas increases in IL-8^[@bib13]^ and IL-6^[@bib14]^ were reported in depressed bipolar patients. In line with this inflammatory phenotype, serum chemokine levels were found to be altered in euthymic bipolar patients, with elevated levels of C--X--C motif chemokine 10 and lower levels of chemokine (C--C motif) ligand 24.^[@bib16]^

Toll-like receptors (TLRs) are a pivotal component of the innate immune system. These receptors comprise of ten members (TLR1-10) in humans and are activated by various components of both bacteria and viruses for example, TLR4 binds lipopolysaccharide in gram-negative bacteria and TLR7 binds single-stranded RNA (ssRNA) from viruses as well as some endogenous proteins.^[@bib17]^ In a cellular context, they are located both at the cell membrane (TLR1, 2, 4, 5 and 6) and also on intracellular endosomes (TLR 3, 7, 8 and 9). The extracellular receptors tend to engage with bacterial components external to the cell. The intracellular TLRs tend to engage with nucleic acids from bacteria and viruses that have penetrated the cell.^[@bib17]^ These receptors tend to form homo- or heterodimers with other TLR members. Following receptor binding, a cellular protein cascade is initiated, which results in the activation of NF-κB among other transcription factors, which in turn transcribes inflammatory cytokines.^[@bib17]^ TLRs are present on various cell types and are found in high numbers on mucosal surfaces (for example, the colonic and bronchial epithelium) and also on monocytic cells in peripheral blood.^[@bib18]^ Altered levels of plasma inflammatory cytokines in schizophrenia and bipolar patients led us to investigate if altered TLR activity may be a possible cause. Our aim was to characterise the activity of various TLRs in peripheral blood in psychotic patients.

Materials and methods
=====================

Subject population
------------------

The study protocol (APC021 2009), including all procedures, was approved by the Cork University Hospital ethics committee. Forty HC were recruited from laboratory or hospital staff. Forty schizophrenia patients and twenty bipolar patients aged between 18--65 years of age, who satisfied DSM-IV (diagnostic and statistical manual of mental disorders) criteria for the diagnosis of schizophrenia and bipolar disorder (based on a structured clinical interview), were recruited from psychiatric clinics and inpatient wards at Cork University Hospital. Individuals with inflammatory diseases, coeliac disease, lactose intolerance, immunodeficiency and individuals who had undergone any abdominal surgery, with the exception of hernia repair and appendectomy were excluded. Each potentially eligible patient donated 20 ml venous blood (between 09:00--12:00 h), and was evaluated by psychiatrist using a full review of clinical history, including current health status, body mass index, family history, current medication and psychiatric evaluation.

Questionnaires and psychiatric rating scales
--------------------------------------------

In the schizophrenia cohort, symptoms were objectively rated by a psychiatrist according to the administered positive and negative symptom scale (PANSS). This is a 30-item scale that measures positive symptoms, negative symptoms, their differential and general psychopathology symptoms. Total overall scores range from 30 to 210, with a cutoff of ⩽60 for mild illness severity, 61 to ⩽75 for moderate severity and \>75 for markedly severe illness.^[@bib19],\ [@bib20]^ The Calgary depression scale for schizophrenia was also completed for all patients to assess comorbid depressive symptomatology. It is an observer-rated scale, with a cutoff of ⩾6 indicating concurrent depression.^[@bib21]^ In the bipolar cohort, symptoms were objectively measured using the Young mania rating scale and the Hamilton depression rating scale. The Young mania rating scale is a clinician-administered scale that rates the severity of mania. There are 11 items in total, measuring symptoms such as elevated mood, irritability, sleep, behaviour and insight. The total achievable score is 60, with a score of ⩽7 indicating remission. The Hamilton depression rating scale is also a clinician-rated scale for assessing the severity of depression. It consists of 17 items (including disturbances in mood, sleep, appetite and weight, anxiety, agitation, somatic symptoms and suicidal ideation). There is a maximum possible score of 45. A score of ⩽7 indicates remission; 8--13 mild depression; 14--18 moderate depression; 19--23 severe depression and \>24 very severe depression.^[@bib22],\ [@bib23],\ [@bib24]^

Plasma isolation and whole-blood culture
----------------------------------------

Whole blood (15 ml of the 20 ml collected) was added to an equal volume of Histopaque 1077 (Sigma, St Louis, MO, USA) in a sterile 50-ml tube and centrifuged at 400 *g* for 30 min at room temperature. Plasma on the upper layer was transferred to a separate tube and stored at −80 °C for future use. Whole blood (2 ml of the 20 ml collected) was diluted 1:10 in Dulbecco\'s Modified Eagle\'s Medium (Gibco, Dublin, Ireland). Blood was aliquoted into 24-well plates, and cultured in 37 °C incubator with 5% CO~2~. Each blood sample was cultured in Dulbecco\'s Modified Eagle\'s Medium cell culture medium supplemented with 10% Foetal Calf Serum with or without the following TLR ligands from Human TLR agonist kit (InvivoGen, San Diego, CA, USA) for 24 h: TLR1/2---palmitoyl-3-cysteine-serine-lysine 4; TLR2---heat-killed *Listeria Monocytogenes*; TLR3---polyriboinosinic polyribocytidylic acid; TLR4---lipopolysaccharide; TLR5---*Salmonella typhimurium* Flagellin; TLR6/2---Pam~2~CGDPKHPKSF (FSL-1); TLR7---Imiquimod; TLR8---ssRNA40; TLR9---ODN2006. Agonists were reconstituted in endotoxin-free water (supplied) with a final concentration of 1 μg ml^−1^ except for HKLM (10^8^ cells), Poly I:C 10 μg ml^−1^ and ODN2006 5 μ. Each treatment was carried out in duplicate. After the indicated culture period, supernatant from both untreated and stimulated cells was aspirated and stored at −80 °C for cytokine analysis at a later date.

Enzyme-linked immunosorbent assay
---------------------------------

Measurements of pro-inflammatory cytokines IL-1β, IL-6, IL-8 and TNFα in both plasma and following TLR agonist stimulation of whole blood was carried out using the Meso Scale Discovery 4-plex human pro-inflammatory kit II (Meso Scale Discovery, Gaithersburg, MD, USA). Plasma C-reactive protein and serum amyloid A were also measured using Meso Scale Discovery kits. Enzyme-linked immunosorbent assay plates were analysed using the Sector 2400 imager from Meso Scale Discovery. This is an ultra-sensitive method, which has a detection limit for IL-1β of 0.3 pg ml^−1^, IL-6 of 0.3 pg ml^−1^, IL-8 of 1.0 pg ml^−1^ and TNFα of 0.3 pg ml^−1^. Plasma cortisol was measured using the cortisol enzyme immunoassay kit (Assay Designs, Ann Arbor, MI, USA) with a detection limit of 26.99 pg ml^−1^.

Statistical analysis
--------------------

The sample size was determined by a power calculation based on our previous data and aimed at detecting differences between schizophrenia patients, bipolar patients and HC at the 0.05 level. Enzyme-linked immunosorbent assay data were expressed as mean±s.e.m. and plotted as a histogram showing HC, schizophrenia and bipolar patients for each TLR and cytokine analysed. All statistical analysis was carried out using GraphPad Prism for Windows (Version 5, La Jolla, CA, USA). Before analysis, the data were examined for normality using the Kolmogorov--Smirnov test. Plasma cytokine levels were compared using one-way analysis of variance (ANOVA) with a Bonferroni *post-hoc* test, differences were considered significant at *P*\<0.05. Differences between the schizophrenia, bipolar and control groups for TLR-agonist-induced release of cytokines were determined using two-way ANOVA with a Bonferroni *post-hoc* test.

Results
=======

Demographic data
----------------

Demographic data are shown in [Table 1](#tbl1){ref-type="table"} while information on medications is shown in [Table 2](#tbl2){ref-type="table"}. No significant difference was found between the groups for age ([Table 1](#tbl1){ref-type="table"}). A significant difference was found between the groups for weight (*P*=0.0008) and, as a result, for body mass index (*P*=0.0026) using ANOVA. The schizophrenia cohort significantly weighed more than HC (*P*\<0.001) ([Table 1](#tbl1){ref-type="table"}). In our cohort of 40 patients with schizophrenia, 20 patients had mild illness severity, 13 had moderate and 7 had severe illness severity according to the above cutoffs using the PANSS rating scale. The average total score for PANSS was 60.36±2.45, indicating the average severity was mild.

Of the schizophrenia cohort, 19 patients had a previous clinical diagnosis of depression according to DSM-IV criteria compared with 20 of the bipolar cohort and none of the HC. Using the Calgary depression scale for schizophrenia, a total of nine of our schizophrenia cohort satisfied a diagnosis of depression according to these criteria.^[@bib21]^ Using the Young mania rating scale and Hamilton depression rating scale to assess bipolar symptoms, a total of seven patients were in disease remission according to cutoffs of ⩽7 on both these scales. Seven patients scored ⩾8 on the Young mania rating scale indicating manic relapse. Six patients scored \>7 on the Hamilton depression rating scale indicating depressive relapse. Within the control group, three had a family history of depression, compared with nine of the schizophrenia group and six of the bipolar group. In the schizophrenia group, 11 patients had a family history of mood disorder (2 bipolar disorder and 9 unipolar depression) while 15 of the bipolar patients had a family history of mood disorder (9 bipolar disorder and 6 unipolar depression). None of the control group had a family history of psychosis compared with 11 of the schizophrenia group and 3 of the bipolar group ([Table 1](#tbl1){ref-type="table"}).

Plasma cytokine, acute phase proteins and cortisol levels
---------------------------------------------------------

Plasma from HC, schizophrenia and bipolar patients was analyzed for cytokines, acute phase proteins and cortisol. ANOVA confirmed that there were no significant differences in the levels of cortisol between groups ([Figure 1a](#fig1){ref-type="fig"}). ANOVA showed a significant difference in plasma IL-6 levels (*P*=0.031), IL-8 levels (*P*=0.0014) and TNFα levels (*P*=0.0007). *Post-hoc* tests showed that bipolar patients had elevated levels of plasma IL-6 (*P*\<0.05) compared with HC while schizophrenia patients had elevated levels of plasma TNFα (*P*\<0.001) compared with HC ([Figure 1b](#fig1){ref-type="fig"}). ANOVA showed significant differences in plasma C-reactive protein levels (*P*=0.0028) and serum amyloid A levels (*P*=0.002) between groups. *Post-hoc* tests revealed that bipolar patients had elevated plasma levels of both C-reactive protein (*P*\<0.01) and serum amyloid A (*P*\<0.001) compared with HC. These differences remain significant when body mass index is added as a covariate.

TLR agonist cytokine release
----------------------------

Supernatants from whole-blood treatments with TLR agonists of HC, schizophrenia and bipolar patients were analysed for levels of four different pro-inflammatory cytokines IL-1β, IL-6, IL-8 and TNFα. Two-way ANOVA demonstrated a significant effect of both disease state (*F*~2,\ 1903~=25.92, *P*\<0.0001) and TLR agonist treatment (*F*~9,\ 1903~=169.5, *P*\<0.0001) with a significant interaction (*F*~18,\ 1903~=7.05, *P*\<0.0001) between the two factors for IL-1β levels. A significant effect of both disease state (*F*~2,\ 1892~=5.81, *P*=0.0031) and treatment (*F*~9,\ 1892~=198.9, *P*\<0.001) with a significant interaction (*F*~18,\ 1892~=4.63, *P*\<0.0001) between the two factors was found for IL-6 levels. Two-way ANOVA demonstrated a significant effect of both disease state (*F*~2,\ 1924~=35.69, *P*\<0.0001) and treatment (*F*~9,\ 1924~=57.23, *P*\<0.0001) but not a significant interaction (*F*~18,\ 1924~=1.132, *P*\>0.05) between the two factors for IL-8 levels. A significant effect of both disease state (*F*~2,\ 1927~=32.44, *P*\<0.0001) and treatment (*F*~9,\ 1927~=135.8, *P*\<0.0001) with a significant interaction (*F*~18,\ 1927~=8.542, *P*\<0.0001) between the two factors for TNFα levels was also found.

*Post-hoc* analysis of individual treatments test revealed significant differences between schizophrenia patients, bipolar patients and HC. In the untreated blood, levels of IL-8 were found to be significantly higher in both schizophrenia (4562±255 pg ml^−1^; *P*\<0.001) and bipolar disorder patients (4283±117 pg ml^−1^; *P*\<0.05) compared withHC (3077±298 pg ml^−1^) ([Figure 2a](#fig2){ref-type="fig"}). No significant differences were found in cytokine release following treatment with the TLR1/2 agonist Pam3Csk ([Figure 2b](#fig2){ref-type="fig"}). IL-1β release was found to be significantly elevated in schizophrenia (1949±167 pg ml^−1^; *P*\<0.001) and bipolar disorder patients (2597±267 pg ml^−1^; *P*\<0.001) compared with HC blood (957±114 pg ml^−1^) following treatment with the TLR2 agonist HKLM. In addition, IL-1β release was significantly greater in bipolar disorder compared with schizophrenia patients (*P*\<0.001).

IL-6 release was significantly elevated in schizophrenia (2675±259 pg ml^−1^; *P*\<0.05) and bipolar disorder patients (3810±262 pg ml^−1^; *P*\<0.001) compared with HC blood (2040±208 pg ml^−1^). In addition, IL-6 release was significantly greater in bipolar disorder compared with schizophrenia patients (*P*\<0.001). TNFα release was found to be significantly elevated in schizophrenia (2197±247 pg ml^−1^; *P*\<0.001) and bipolar disorder patients (3753±461 pg ml^−1^; *P*\<0.001) compared with HC blood (1134±164 pg ml^−1^). In addition, TNFα release was greater in bipolar disorder patients compared schizophrenia patients (*P*\<0.001) ([Figure 2c](#fig2){ref-type="fig"}).

No significant differences were found in cytokine release following treatment with the TLR3 agonist Poly I:C ([Figure 2d](#fig2){ref-type="fig"}). IL-1β was found to be significantly elevated in schizophrenia (2409±181 pg ml^−1^; *P*\<0.05) and bipolar disorder patients (2859±260 pg ml^−1^; *P*\<0.001) compared with HC (1961±131 pg ml^−1^) following treatment with the TLR4 agonist lipopolysaccharide. IL-8 release was significantly lower in bipolar disorder patients (4875±77 pg ml^−1^) compared with schizophrenia blood (6146±231 pg ml^−1^). TNFα release was found to be significantly elevated in bipolar disorder patients (3332±376 pg ml^−1^; *P*\<0.001) compared with HC blood (2361±164 pg ml^−1^). In addition, TNFα release was significantly greater in bipolar disorder patients compared with schizophrenia blood (*P*\<0.05) ([Figure 2e](#fig2){ref-type="fig"}).

No significant differences in cytokine release compared with controls were found following treatment with the TLR5 agonist flagellin. However, IL-8 release was significantly lower in bipolar disorder patients (4690±89 pg ml^−1^; *P*\<0.05) compared with schizophrenia (5934±247 pg ml^−1^). In addition, TNFα release was greater in bipolar disorder patients (1860±375 pg ml^−1^; *P*\<0.05) compared with schizophrenia (1196±121 pg ml^−1^) ([Figure 3a](#fig3){ref-type="fig"}). No significant differences in cytokine release were found following treatment with the TLR6/2 agonist FSL1 ([Figure 3b](#fig3){ref-type="fig"}) or the TLR7 agonist Imiquimod ([Figure 3c](#fig3){ref-type="fig"}). IL-1β release was found to be significantly elevated in schizophrenia (1835±203 pg ml^−1^; *P*\<0.001) and bipolar disorder patients (2282±232 pg ml^−1^; *P*\<0.001) compared with HC (1181±120 pg ml^−1^) following treatment with the TLR8 agonist ssRNA40.

IL-6 release was found to be significantly elevated in bipolar disorder (2484±253 pg ml^−1^; *P*\<0.05) compared with controls (1631±152 pg ml^−1^). In addition, IL-6 release was greater in bipolar disorder compared with schizophrenia patients (*P*\<0.01). TNFα release was found to be significantly elevated in bipolar disorder patients (2472±323 pg ml^−1^; *P*\<0.001) compared with controls (1132±117 pg ml^−1^) following treatment with the ssRNA40. In addition, TNFα release was greater in bipolar disorder compared with schizophrenia patients (*P*\<0.01) ([Figure 3d](#fig3){ref-type="fig"}). IL-8 release was found to be significantly elevated in schizophrenia patients (2255±339 pg ml^−1^; *P*\<0.05) compared with controls (1104±276 pg ml^−1^) following treatment with the TLR9 agonist ODN2006. In addition, IL-8 release was lower in bipolar disorder compare with schizophrenia patients (*P*\<0.05) ([Figure 3e](#fig3){ref-type="fig"}). Entering body mass index as a covariate did not alter the significance of the findings.

Discussion
==========

The exact pathophysiology of schizophrenia and bipolar disorder is still unknown. Immune activation has been reported in a number of studies for both disorders, showing increases in particular pro-inflammatory cytokines.^[@bib9],\ [@bib12],\ [@bib13]^ Whether this is central to disease progression or is an epiphenomenon is unclear. The cause of the elevations in certain cytokines seen in schizophrenia and bipolar patients has yet to be determined. We hypothesized that TLR activity may be altered in psychiatric patients.

In this study, both schizophrenia and bipolar patients were shown to have elevated plasma cytokines and acute phase proteins. The effects of elevated cytokine levels on the pathophysiology of these disorders remain to be precisely defined. Cytokines are known to have an effect on the HPA axis and stress response.^[@bib25]^ IL-1β, IL-6 and TNFα have all been reported to stimulate secretion of corticotrophin-releasing hormone in rat as well as in humans.^[@bib26],\ [@bib27]^ Cytokines are thought to be able to cross the blood--brain barrier or, at least, stimulate cells at the barrier to release more cytokines within the brain.^[@bib27]^ During development and especially following maternal infection and inflammation, cytokines have been reported to affect cortical neuronal development,^[@bib6],\ [@bib28]^ and, by so doing, may have a sustainable effect.

Whole-blood stimulations revealed a distinct pattern of peripheral TLR activity in both schizophrenia and bipolar patients. It was apparent that the exaggerated effects of HKLM, the TLR2 agonist, were the most striking result in both disorders, with TLR4 and TLR8 activities also enhanced. No differences in TLR1, TLR3, TLR5, TLR6 or TLR7 activity were detected compared with controls. It is known that TLR2 may bind a number of different ligands, especially lipopeptides related to bacterial cell wall components in addition to endogenously released peptides,^[@bib29]^ although a yet undiscovered endogenous or exogenous ligand(s) may also activate this receptor. In this study, we showed that the TLR2 homodimer activity (HKLM) was enhanced as distinct from activities of the TLR1/2 (Pam3Csk) or TLR6/2 (FSL1) heterodimers. It is unclear if ligand(s) for TLRs are present in blood from schizophrenia and bipolar patients under basal conditions, which would have the ability to activate these receptors.

Schizophrenia and bipolar disorder are similar in respects to epidemiology, in particular age of onset, incidence in the population and lifetime duration.^[@bib30]^ In addition, it has become apparent from a number of studies that these disorders share some molecular susceptibility loci.^[@bib30],\ [@bib31]^ As mentioned before, these disorders both display increases in plasma levels of inflammatory markers. At present, it is not certain why schizophrenia and bipolar patients display greater TLR activity compared with controls or why their pattern is so similar. It has been shown that schizophrenia and bipolar patients appear to be particularly susceptible to stress.^[@bib32],\ [@bib33],\ [@bib34],\ [@bib35],\ [@bib36]^ It is apparent from both animal models and clinical studies that chronic stress may affect the immune response.^[@bib37]^ It was reported that repeated social defeat stress enhanced the bactericidal activity of splenic macrophages and led to an increase in the expression of TLR2 and TLR4.^[@bib38]^ The same group also showed that social defeat may activate splenic dendritic cells and enhances TLR activity on these cells as assessed by cytokine output by ligand stimulation.^[@bib39]^ In addition, chronic restraint stress has been shown to result in immune suppression and this was mediated by TLR4.^[@bib40],\ [@bib41]^

It has been shown that cytokines themselves can alter TLR expression.^[@bib42],\ [@bib43]^ Plasma cytokines and acute phase proteins have been shown to be elevated in this cohort of patients and this potentially may explain why there are increases in TLR activity in these patients. Although a number of psychiatric disorders have alterations in the immune system, TLR activity may allow us to differentiate between different disorders, with individual disorders having their own signature TLR increases and decreases. This may lend peripheral TLR activity as a potential biomarker in the diagnosis of psychiatric disorders. The average weight of the schizophrenia cohort was higher than HC. This may be due to antipsychotic drugs, which have been shown to induce weight gain in some patients,^[@bib44]^ but it does not account for the enhanced immune responses in this study.

We have observed in some instances where there are greater increases in a cytokine following ligand stimulation in one disorder over another. A possible explanation for this may be owing to expression or activity differences between disorders of one of the many downstream signalling molecules that lead to activation of transcription factors following TLR stimulation. Alternatively, it may be for epigenetic reasons, such as decreased transcriptional activity in either disorder for particular cytokines. This would imply that when a ligand activates the receptor and initiates the downstream signalling pathway, there would be less transcriptional activity at the promoter of the given cytokine due to epigenetic silencing/modifications.

Limitations of this study include the lack of drug-free patients. This may have implications for the observed immune changes in schizophrenia and bipolar patients. It is known that antipsychotics may have an effect on plasma cytokine levels.^[@bib45]^ As a sizeable number of patients were on one or more antipsychotics in the schizophrenia cohort and a mood stabilizer and/or antipsychotics in the bipolar cohort ([Table 2](#tbl2){ref-type="table"}), it would be difficult to assess the effect of individual drugs on TLR activity. In addition, bipolar patients were not selected on the basis of the phase of the disorder, and so differences may exist between manic and depressive patients, however, the study is not powered to detect these differences. Similarly, schizophrenia patients were not differentiated on illness severity.

This study has provided novel insights into relationships between TLR activation, plasma cytokine levels and clinical phenotype among a well-characterised group of schizophrenia and bipolar patients. While confirming that certain pro-inflammatory cytokine levels are increased in plasma among schizophrenia and bipolar patients, we have gone on to describe, what is to our knowledge for the very first time, distinctive patterns of TLR activity in the periphery of psychotic patients. In summary, the observed increase in TLR activity in psychiatric patients implies that following engagement of these receptors by endogenous or exogenous ligands, there would be a greater release of inflammatory cytokines in psychiatric patients. This increase in inflammation may in turn affect neuronal plasticity as has been demonstrated using animal models.^[@bib5],\ [@bib6],\ [@bib7]^ This study further suggests a link between inflammation and psychosis.
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![Shown is a graph of plasma (**a**) cortisol, (**b**) cytokine and (**c**) acute phase protein levels in healthy controls (Ctrl), schizophrenia (Scz) and bipolar (BP) patients measured using enzyme-linked immunosorbent assay. Data shown are expressed as mean±s.e.m. Statistical differences between groups were determined using ANOVA. ^\*^*P*\<0.05, ^\*\*^*P*\<0.01, ^\*\*\*^*P*\<0.001 vs Ctrl. CRP, plasma C-reactive protein; SAA, serum amyloid A.](tp201137f1){#fig1}

![Shown is a graph of IL-1β, IL-6, IL-8 and TNFα levels in stimulated whole-blood supernatants taken from HC (Ctrl), schizophrenia (Scz) and bipolar (BP) patients measured using enzyme-linked immunosorbent assay following (**a**) no treatment or treatment with the (**b**) TLR1/2 agonist Pam3Csk, (**c**) TLR2 agonist HKLM, (**d**) TLR3 agonist Poly I:C or (**e**) TLR agonist lipopolysaccharide for 24 h. Data shown are expressed as mean±s.e.m. Statistical differences between treatments and disease states were determined using two-way ANOVA with Bonferroni *post-hoc* test. ^\*^*P*\<0.05, ^\*\*\*^*P*\<0.001 vs Ctrl; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, ^\#\#\#^*P*\<0.001 bipolar disorder vs schizophrenia.](tp201137f2){#fig2}

![Shown is a graph of IL-1β, IL-6, IL-8 and TNFα levels in stimulated whole-blood supernatants taken from HC (Ctrl), schizophrenia (Scz) and bipolar (BP) patients measured using enzyme-linked immunosorbent assay following treatment with (**a**) TLR5 agonist Flagellin, (**b**) TLR6/2 agonist FSL1, (**c**) TLR7 agonist Imiquimod, (**d**) TLR8 agonist ssRNA40 or (**e**) TLR9 agonist ODN2006 for 24 h. Data shown are expressed as mean±s.e.m. Statistical differences between treatments and untreated were determined using two-way ANOVA with Bonferroni *post-hoc* test. ^\*^*P*\<0.05, ^\*\*\*^*P*\<0.001 vs Ctrl; ^\#^*P*\<0.05, ^\#\#^*P*\<0.01, bipolar disorder vs schizophrenia.](tp201137f3){#fig3}

###### Demographic data were collected from medical history

                               *Healthy controls (*N=*40)*   *Schizophrenia (*N=*40)*   *Bipolar disorder (*N=*20)*
  --------------------------- ----------------------------- -------------------------- -----------------------------
  Age (years)                          36.20±1.758                 38.33±1.699                  38.50±2.630
  Sex                                   13M, 27F                     24M, 16F                    10M, 10F
  Height (m)                          1.706±0.01618               1.733±0.01141                1.691±0.02084
  Weight (kg)                          69.74±2.591             84.01±2.883^\*\*\*^              75.12±2.664
  BMI (kg m^−2^)                      23.89±0.8261              27.94±0.8507^\*\*^             26.30±0.9255
  PANSS total score                        N/A                      60.36±2.45                      N/A
  YMRS                                     N/A                         N/A                       16±2.517
  HDRS                                     N/A                         N/A                        9±2.646
  History of depression                     0                           19                          20
  Family history psychosis                  0                           11                           3
  Family history depression                 3                           9                            6
  Family history bipolar                    0                           2                            9

Abbreviations: BMI, body mass index; HDRS, Hamilton depression rating scale; N/A, not applicable; PANSS, positive and negative symptom scale; YMRS, Young mania rating scale.

Data from psychiatric rating scales are also shown. Data are expressed as mean±s.e.m. Analysis of variance was used to determine significant differences.

^\*\*^*P*\<0.01 vs Ctrl.

^\*\*\*^*P*\<0.001 vs Ctrl.

###### Shown is a list of psychiatric medications taken by schizophrenia and bipolar patients

                                 *Schizophrenia*   *Bipolar disorder*
  ------------------------------ ----------------- --------------------
  One antipsychotic              26                13
  Two antipsychotics             13                4
  Three antipsychotics           1                 0
  No antipsychotic               1                 3
  Clozapine                      18                1
  Olanzapine                     9                 5
  Risperidone                    8                 3
  Amisulpride                    4                 0
  Haloperidol                    4                 3
  Fluphenazine                   3                 0
  Quetiapine                     2                 7
  Aripiprazole                   2                 1
  Trifluoperazine                1                 0
  Sertindole                     1                 0
  Sulpride                       1                 0
  SSRIs                          9                 0
  NARIs                          1                 0
  SNRI                           1                 2
  TCAs                           1                 2
  Lithium                        0                 11
  Valproate                      2                 8
  Lamotrignine                   0                 4
  Carbamazepine                  2                 0
  Benzodiazepine                 10                14
  Non-benzodiazepine hypnotics   3                 4

NARIs, noradrenaline reuptake inhibitors; SNRI, selective noradrenaline reuptake inhibitors; SSRIs, selective serotonin reuptake inhibitors; TCAs, tricyclic antidepressants.

This includes the total numbers on antipsychotics and numbers on individual antipsychotics as well as antidepressants, mood stabilizers and hypnotics.
